These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Investigating the stereochemistry of binding to HIV-1 protease with inhibitors containing isomers of 4-amino-3-hydroxy-5-phenylpentanoic acid. Raju B; Deshpande MS Biochem Biophys Res Commun; 1991 Oct; 180(1):187-90. PubMed ID: 1930215 [TBL] [Abstract][Full Text] [Related]
3. Total chemical synthesis of a D-enzyme: the enantiomers of HIV-1 protease show reciprocal chiral substrate specificity [corrected]. Milton RC; Milton SC; Kent SB Science; 1992 Jun; 256(5062):1445-8. PubMed ID: 1604320 [TBL] [Abstract][Full Text] [Related]
4. HIVdb: a database of the structures of human immunodeficiency virus protease. Vondrasek J; Wlodawer A Proteins; 2002 Dec; 49(4):429-31. PubMed ID: 12402352 [No Abstract] [Full Text] [Related]
5. Probing the S1/S1' substrate binding pocket geometry of HIV-1 protease with modified aspartic acid analogues. Short GF; Laikhter AL; Lodder M; Shayo Y; Arslan T; Hecht SM Biochemistry; 2000 Aug; 39(30):8768-81. PubMed ID: 10913288 [TBL] [Abstract][Full Text] [Related]
6. A heterologous substrate assay for the HIV-1 protease engineered in Escherichia coli. Stebbins J; Deckman IC; Richardson SB; Debouck C Anal Biochem; 1996 Nov; 242(1):90-4. PubMed ID: 8923970 [TBL] [Abstract][Full Text] [Related]
8. Comparative studies on inhibitors of HIV protease: a target for drug design. Jayaraman S; Shah K In Silico Biol; 2008; 8(5-6):427-47. PubMed ID: 19374129 [TBL] [Abstract][Full Text] [Related]
9. Switching between allosteric and dimerization inhibition of HIV-1 protease. Bowman MJ; Byrne S; Chmielewski J Chem Biol; 2005 Apr; 12(4):439-44. PubMed ID: 15850980 [TBL] [Abstract][Full Text] [Related]
10. Anomalous adsorptive properties of HIV protease: indication of two-dimensional crystallization? Cígler P; Král V; Kozísek M; Konvalinka J; Mirsky VM Colloids Surf B Biointerfaces; 2008 Jun; 64(1):145-9. PubMed ID: 18304786 [TBL] [Abstract][Full Text] [Related]
11. [Development of HIV protease inhibitors as anti AIDS drugs: molecular design based on substrate transition state]. Kiso Y Tanpakushitsu Kakusan Koso; 1998 May; 43(6):725-33. PubMed ID: 9612066 [No Abstract] [Full Text] [Related]
13. Conformational flexibility in the flap domains of ligand-free HIV protease. Heaslet H; Rosenfeld R; Giffin M; Lin YC; Tam K; Torbett BE; Elder JH; McRee DE; Stout CD Acta Crystallogr D Biol Crystallogr; 2007 Aug; 63(Pt 8):866-75. PubMed ID: 17642513 [TBL] [Abstract][Full Text] [Related]
14. Design, asymmetric synthesis, and evaluation of pseudosymmetric sulfoximine inhibitors against HIV-1 protease. Lu D; Sham YY; Vince R Bioorg Med Chem; 2010 Mar; 18(5):2037-48. PubMed ID: 20138769 [TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, and X-ray crystallographic analysis of a novel class of HIV-1 protease inhibitors. Ganguly AK; Alluri SS; Caroccia D; Biswas D; Wang CH; Kang E; Zhang Y; McPhail AT; Carroll SS; Burlein C; Munshi V; Orth P; Strickland C J Med Chem; 2011 Oct; 54(20):7176-83. PubMed ID: 21916489 [TBL] [Abstract][Full Text] [Related]
16. Peptidomimetic therapeutic agents targeting the protease enzyme of the human immunodeficiency virus and hepatitis C virus. Tsantrizos YS Acc Chem Res; 2008 Oct; 41(10):1252-63. PubMed ID: 18681464 [TBL] [Abstract][Full Text] [Related]
19. A new class of HIV-1 protease inhibitors containing a tertiary alcohol in the transition-state mimicking scaffold. Ekegren JK; Unge T; Safa MZ; Wallberg H; Samuelsson B; Hallberg A J Med Chem; 2005 Dec; 48(25):8098-102. PubMed ID: 16335934 [TBL] [Abstract][Full Text] [Related]
20. Design and synthesis of sulfoximine based inhibitors for HIV-1 protease. Raza A; Sham YY; Vince R Bioorg Med Chem Lett; 2008 Oct; 18(20):5406-10. PubMed ID: 18829317 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]